Late cardiotoxicity after treatment for a malignant bone tumor

Medical and Pediatric Oncology

Volumn 26, Issue 4, 1996, Pages 230-237

  Postma, A ^a,b   Bink Boelkens, M T E ^a   Beaufort Krol, G C M ^a   Kengen, R A M ^a   Elzenga, N J ^a   Schasfoort van Leeuwen, M J M ^a   Schraffordt Koops, H ^a   Kamps, W A ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anthracyclines; cardiotoxicity; long term effects

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; ELECTROCARDIOGRAM; FEMALE; HEART EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SCINTIANGIOGRAPHY;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARRHYTHMIA; BLEOMYCIN; BODY SURFACE AREA; BONE NEOPLASMS; CHILD; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DILATATION, PATHOLOGIC; DOXORUBICIN; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART; HEART DISEASES; HEART RATE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MYOCARDIUM; RADIONUCLIDE ANGIOGRAPHY; STROKE VOLUME; SURVIVORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0029868160     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199604)26:4<230::AID-MPO2>3.0.CO;2-K     Document Type: Article

References (27)

1. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, Mckone R, Lipshultz SE: Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116:144-147, 1990.
2. Stemherz LJ, Steinherz P, Tan CTC, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991.
3. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphobiastic leukemia in childhood. N Engl J Med 324: 808-815, 1991.
4. Dresdale A, Bonow RO, Wesley R, Palmeri ST, Barr L, Mathison D, D'Angelo T, Rosenberg SA: Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from post surgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52: 51-60, 1983.
5. Minow RA, Benjamin RS, Lee ET, Gottlieb JA: Adriamycin cardiomyopathy-risk factors. Cancer 39:1397-1402, 1977.
6. Myers CE, Chabner BA: Anthracyclines. In Chabner BA, Collins JE (eds): "Cancer Chemotherapy, Principles and Practice." Philadelphia: J.B. Lippincott, 1990, pp. 356-381.
7. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G: Electro cardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73-77, 1992.
8. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC: Chemotherapy en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37:1-11, 1976.
9. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C: Pre-operative chemotherapy for osteogenic sarcoma. Cancer 49:1221-1230, 1982.
10. Breithardt G, Cain ME, Ee-sherif N, Flowers NC, Hombach V, Janse M, Simson MB, Steinbeck G: Standards for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography: a statement by a task force committee of the European Society of Cardiology, the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 17:999-1006, 1991.
11. Gomes JA, Winters SL, Ip J: Signal averaging of the surface QRS complex: practical applications. J Cardiovasc Blectrophysiol 2:316-330. 1991.
12. Lown B, Wolf M: Approaches to sudden death from coronary heart disease. Circulation 44:130-142, 1971.
13. Bennett DH, Evains DW, Rai MVJ: Echoardiographoc left ventricular dimensions in pressure and volume overload. Their use in assessing aortic stenosis. Br Heart J 37:971-977, 1975.
14. Daniels O, Voogd PJ, Gussenhoven WJ, De Knecht S, Rijsterborgh H, Van Lier H: Left ventricular inner dimensions in normal children. In Sobotka MA (ed): "Anthracycline Cardiotoxicity in children; an echocardiographic study." Thesis State University Leiden, The Netherlands, 1991, pp 97-100.
15. Van Eys J: Malnutrition in pediatric oncology. In Newell GR, Ellison NM (eds): "Nutrition and Cancer: Etiology and Treatment." New York: Raven Press, 1981, pp. 411-429.
16. Von Hoff DD, Rozencweig M, Piccart M: The cardiotoxicity of anticancer agents. Semin Oncol 9:23-33, 1982.
17. Colvin M, Chabner BA: Alkylating Agents, In: Chabner BA, Collins JM (eds: "Cancer Chemotherapy, Principles and Practice." Philadelphia: J.B. Lippincott, 1990, pp. 276-313.
18. Goldberg M, Antin JH, Guinan EC, Rappeport JM: Cyclophosphamide cardiotoxicity an analysis of dosing as a risk factor. Blood 68:1114-1118, 1986.
19. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT: Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215-1223, 1991.
20. Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB: Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 11:1906-1910, 1993.
21. Tamminga RYJ, Bink-Boelkens MTE, Kievit J: Ventricular late potentials: another expression of cardiotoxicity of cytostatic drugs in children? Int J Cardiol 36:283-288, 1992.
22. Saul JP, Arai Y, Berger RD, Lilly LS, Colucci WS, Cohen RJ: Assessment of autonomic regulation in chronic congestive heart failure by heart spectral analysis. Am J Cardiol 61:1292-1299, 1988.
23. Kleiger RE, Miller JP, Bigger JT, Moss AJ: and the Multicenter post-infarction research group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59:256-262, 1987.
24. Hrubhesky WJM, Fader DJ, Berestka JS, Sommer M, Hayes J, Cope FO: Dhiminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation 84:697-707, 1991.
25. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 327:685-691, 1992.
26. Schwartz RG, McKenzie WB, Alexander J, Sager P. D'Souze A, Manatunga A, Schwartz PE. Berger HJ, Setaro J, Surking L, Wackers FJT, Zaret BL: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 82:1109-1118, 1987.
27. Wiles HB: Nuclear Cardiology. In Garson A., Bricker JT, McNamara DG (eds): "The Science and Practice of Pediatric Cardiology." Philadelphia: Lea and Febiger, 1990, pp. 836-851.